Ifinatamab Deruxtecan (DS-7300a) (CAS: 2484870-92-8)
Ifinatamab deruxtecan (DS-7300a) is an investigational antibody-drug conjugate (ADC) designed for targeted cancer therapy. It consists of a humanized monoclonal antibody targeting B7-H3, a protein overexpressed in various cancers, linked to deruxtecan (DXd), a potent topoisomerase I inhibitor.
Key Features:
- Targeted Therapy: The antibody binds specifically to B7-H3 on cancer cells, delivering the cytotoxic agent directly to the tumor site.
- Cytotoxic Payload: Deruxtecan inhibits topoisomerase I, causing DNA damage and inducing cancer cell death.
- Enhanced Efficacy: This ADC approach ensures higher concentrations of the cytotoxic agent at the tumor, improving effectiveness and reducing systemic toxicity.
Applications:
- Solid Tumors: Investigated for treating cancers like non-small cell lung cancer, esophageal cancer, and small cell lung cancer that express B7-H3.
- Clinical Trials: Currently undergoing clinical trials to assess its safety, tolerability, and effectiveness in patients with advanced solid tumors.
Handling and Storage:
- Storage: Store at -20°C, protected from light and moisture.
- Handling: Use standard laboratory precautions when handling this reagent.
AxisPharm offers 5000+ PEG Linkers with high purity. Different kinds of PEG Reagents may be available by custom synthesis.